The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing
Our study demonstrated the potential antineuroblastoma activity of the GADEKILL, supporting its therapeutic use, particularly in the context of relapsed/refractory R/R HR-NB with low GD2 expression.
Authors
- Eleonora Ciampi (ORCID: https://orcid.org/0009-0003-5044-3184)
- C. Brignole
- Fabio Morandi (ORCID: https://orcid.org/0000-0002-2849-7595)
- Stefano Giardino (ORCID: https://orcid.org/0000-0002-7788-6407)
- Fabio Pastorino (ORCID: https://orcid.org/0000-0002-8312-808X)
- Martina Della Lastra
- Irma Airoldi (ORCID: https://orcid.org/0000-0002-4352-8396)
- Maura Faraci
Institutions
- Istituto Giannina Gaslini (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3389/fimmu.2026.1755500
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute